Direct Effects of Thyroid Hormones on Hepatic Lipid Metabolism

Overview

Journal Nat Rev Endocrinol

Specialty Endocrinology

Date 2018 Feb 24

PMID 29472712

Citations 240

Authors

Rohit A Sinha

Brijesh K Singh

Paul M Yen

Affiliations

Soon will be listed here.

Abstract

It has been known for a long time that thyroid hormones have prominent effects on hepatic fatty acid and cholesterol synthesis and metabolism. Indeed, hypothyroidism has been associated with increased serum levels of triglycerides and cholesterol as well as non-alcoholic fatty liver disease (NAFLD). Advances in areas such as cell imaging, autophagy and metabolomics have generated a more detailed and comprehensive picture of thyroid-hormone-mediated regulation of hepatic lipid metabolism at the molecular level. In this Review, we describe and summarize the key features of direct thyroid hormone regulation of lipogenesis, fatty acid β-oxidation, cholesterol synthesis and the reverse cholesterol transport pathway in normal and altered thyroid hormone states. Thyroid hormone mediates these effects at the transcriptional and post-translational levels and via autophagy. Given these potentially beneficial effects on lipid metabolism, it is possible that thyroid hormone analogues and/or mimetics might be useful for the treatment of metabolic diseases involving the liver, such as hypercholesterolaemia and NAFLD.

Citing Articles

Seed Extract Attenuates Glycolipid Metabolism Disorder in Hyperlipidemia Mice Through PPAR Signaling Pathway Based on Metabolomics and Network Pharmacology.

Wang M, Yang T, Xiang Y, Pang J, Wang Y, Sun D Foods. 2025; 14(5).

PMID: 40077474 PMC: 11899454. DOI: 10.3390/foods14050770.

Role of serum fasting glucagon in hypothyroidism-related nonalcoholic fatty liver disease.

El-Eshmawy M, Barakat A, El-Baiomy A, El-Naga M, Elbasiony M Nutr Metab (Lond). 2025; 22(1):19.

PMID: 40069760 PMC: 11899932. DOI: 10.1186/s12986-025-00899-z.

Integrated computational analysis of molecular mechanisms underlying perfluorooctane sulfonic acid induced thyroid toxicity.

Li H, Yu B, Yuan Y, Chen N, Guo H, Zhang H Sci Rep. 2025; 15(1):7920.

PMID: 40050647 PMC: 11885520. DOI: 10.1038/s41598-025-92678-2.

Pathological features of non-alcoholic steatohepatitis in a pediatric patient with heterozygous familial hypobetalipoproteinemia: A case report.

Miyamoto K, Kondo S, Kondo T, Ishikawa R, Tani R, Inoue T World J Hepatol. 2025; 17(2):103299.

PMID: 40027560 PMC: 11866159. DOI: 10.4254/wjh.v17.i2.103299.

Two or three weeks of thyroid hormone withdrawal before initial I therapy for patients with differentiated thyroid carcinoma?.

Wang Y, Huang S, Huang R BMC Cancer. 2025; 25(1):370.

PMID: 40022060 PMC: 11869641. DOI: 10.1186/s12885-024-13313-3.

References

Grasselli E, Voci A, Canesi L, Goglia F, Ravera S, Panfoli I . Non-receptor-mediated actions are responsible for the lipid-lowering effects of iodothyronines in FaO rat hepatoma cells. J Endocrinol. 2011; 210(1):59-69. DOI: 10.1530/JOE-11-0074. View

Finan B, Clemmensen C, Zhu Z, Stemmer K, Gauthier K, Muller L . Chemical Hybridization of Glucagon and Thyroid Hormone Optimizes Therapeutic Impact for Metabolic Disease. Cell. 2016; 167(3):843-857.e14. DOI: 10.1016/j.cell.2016.09.014. View

Mullur R, Liu Y, Brent G . Thyroid hormone regulation of metabolism. Physiol Rev. 2014; 94(2):355-82. PMC: 4044302. DOI: 10.1152/physrev.00030.2013. View

Lopez D, Abisambra Socarras J, Bedi M, Ness G . Activation of the hepatic LDL receptor promoter by thyroid hormone. Biochim Biophys Acta. 2007; 1771(9):1216-25. DOI: 10.1016/j.bbalip.2007.05.001. View

Torun E, Ozgen I, Gokce S, Aydin S, Cesur Y . Thyroid hormone levels in obese children and adolescents with non-alcoholic fatty liver disease. J Clin Res Pediatr Endocrinol. 2014; 6(1):34-9. PMC: 3986737. DOI: 10.4274/Jcrpe.1155. View

Chng C, Lim A, Tan H, Kovalik J, Tham K, Bee Y . Physiological and Metabolic Changes During the Transition from Hyperthyroidism to Euthyroidism in Graves' Disease. Thyroid. 2016; 26(10):1422-1430. DOI: 10.1089/thy.2015.0602. View

Ness G, Pendleton L, Li Y, Chiang J . Effect of thyroid hormone on hepatic cholesterol 7 alpha hydroxylase, LDL receptor, HMG-CoA reductase, farnesyl pyrophosphate synthetase and apolipoprotein A-I mRNA levels in hypophysectomized rats. Biochem Biophys Res Commun. 1990; 172(3):1150-6. DOI: 10.1016/0006-291x(90)91568-d. View

Grasselli E, Voci A, Demori I, Vecchione G, Compalati A, Gallo G . Triglyceride Mobilization from Lipid Droplets Sustains the Anti-Steatotic Action of Iodothyronines in Cultured Rat Hepatocytes. Front Physiol. 2016; 6:418. PMC: 4709507. DOI: 10.3389/fphys.2015.00418. View

Trost S, Swanson E, Gloss B, Zhang H, Volodarsky T, Grover G . The thyroid hormone receptor-beta-selective agonist GC-1 differentially affects plasma lipids and cardiac activity. Endocrinology. 2000; 141(9):3057-64. DOI: 10.1210/endo.141.9.7681. View

10.

Shimizu H, Astapova I, Ye F, Bilban M, Cohen R, Hollenberg A . NCoR1 and SMRT play unique roles in thyroid hormone action in vivo. Mol Cell Biol. 2014; 35(3):555-65. PMC: 4285426. DOI: 10.1128/MCB.01208-14. View

11.

Tseng Y, Ke P, Liao C, Wu S, Chi H, Tsai C . Chromosome 19 open reading frame 80 is upregulated by thyroid hormone and modulates autophagy and lipid metabolism. Autophagy. 2013; 10(1):20-31. PMC: 4389877. DOI: 10.4161/auto.26126. View

12.

Chung G, Kim D, Kim W, Yim J, Park M, Kim Y . Non-alcoholic fatty liver disease across the spectrum of hypothyroidism. J Hepatol. 2012; 57(1):150-6. DOI: 10.1016/j.jhep.2012.02.027. View

13.

Lagrost L . Regulation of cholesteryl ester transfer protein (CETP) activity: review of in vitro and in vivo studies. Biochim Biophys Acta. 1994; 1215(3):209-36. DOI: 10.1016/0005-2760(94)90047-7. View

14.

Quiroga A, Lehner R . Liver triacylglycerol lipases. Biochim Biophys Acta. 2011; 1821(5):762-9. DOI: 10.1016/j.bbalip.2011.09.007. View

15.

Thakran S, Sharma P, Attia R, Hori R, Deng X, Elam M . Role of sirtuin 1 in the regulation of hepatic gene expression by thyroid hormone. J Biol Chem. 2012; 288(2):807-18. PMC: 3543030. DOI: 10.1074/jbc.M112.437970. View

16.

Perra A, Simbula G, Simbula M, Pibiri M, Kowalik M, Sulas P . Thyroid hormone (T3) and TRbeta agonist GC-1 inhibit/reverse nonalcoholic fatty liver in rats. FASEB J. 2008; 22(8):2981-9. DOI: 10.1096/fj.08-108464. View

17.

Vergani L . Lipid lowering effects of iodothyronines: In vivo and in vitro studies on rat liver. World J Hepatol. 2014; 6(4):169-77. PMC: 4009472. DOI: 10.4254/wjh.v6.i4.169. View

18.

Tao Y, Gu H, Wu J, Sui J . Thyroid function is associated with non-alcoholic fatty liver disease in euthyroid subjects. Endocr Res. 2014; 40(2):74-8. DOI: 10.3109/07435800.2014.952014. View

19.

Jekabsons M, Gregoire F, Warden C, Horwitz B . T(3) stimulates resting metabolism and UCP-2 and UCP-3 mRNA but not nonphosphorylating mitochondrial respiration in mice. Am J Physiol. 1999; 277(2):E380-9. DOI: 10.1152/ajpendo.1999.277.2.E380. View

20.

Bryzgalova G, Effendic S, Khan A, Rehnmark S, Barbounis P, Boulet J . Anti-obesity, anti-diabetic, and lipid lowering effects of the thyroid receptor beta subtype selective agonist KB-141. J Steroid Biochem Mol Biol. 2008; 111(3-5):262-7. DOI: 10.1016/j.jsbmb.2008.06.010. View